Errata

Inhibitory Potencies of 1,4-Dihydropyridine Calcium Antagonists to P-Glycoprotein-Mediated Transport: Comparison with the Effects on CYP3A4. By Miki Katoh, Miki Nakajima, Hiroshi Yamazaki, and Tsuyoshi Yokoi. *Pharm. Res.* **17**(10): 1189–1197 (2000).

Figure 5 that appears on p. 1193 is incorrect. The correct figure is shown below.

Fig. 5. Transcellular transport (A) and intracellular accumulation at 3.0 hr (B) of [^{3}H]digoxin (35 nM) across monolayers of LLC-PK$_1$ ($\bigcirc$, $\triangledown$) and LLC-GA5-COL150 ($\bullet$, $\blacktriangle$) cells. A. $\bigcirc$, $\bullet$, the basolateral-to-apical transport; $\triangledown$, $\blacktriangle$, the apical-to-basolateral transport. B. Hatched bar, [^{3}H]digoxin was added to the medium of the basolateral side; open bar, [^{3}H]digoxin was added to the medium of the apical side. Data represent the mean ± SE of three independent measurements.

On p. 1192 of the same issue, the caption to Fig. 4 contains errors. The correct caption is given below.

Fig. 4. Concentration-dependent inhibition of the net transport of 35 nM [^{3}H]daunorubicin by the 1,4-dihydropyridine calcium antagonists at 3.0 hr in LLC-GA5-COL150 cells. $\bullet$, 1. nicardipine; $\bigcirc$, 5. benidipine; $\blacktriangle$, 8. manidipine; $\triangle$, 9. barnidipine; $\blacksquare$, 10. (+)-efonidipine; $\square$, 11. (−)-efonidipine; $\blacklozenge$, 12. amlodipine. The inhibitors ranged 5.0–50 μM. The IC$_{50}$ values of 2. (+)-nilvadipine, 3. (−)-nilvadipine, 4. nifedipine, 6. nisoldipine, 7. nitrendipine, 13. felodipine, 14. cilnidipine, 15. (+)-aranidipine, 16. (−)-aranidipine, and 17. (±)-aranidipine were >50 μM. Data represent the mean of three independent measurements.

The Effect of Gelatin Cross-Linking on the Bioequivalence of Hard and Soft Gelatin Acetaminophen Capsules. By Marvin C. Meyer, Arthur B. Straughn, Ramakant M. Mhatre, Ajaz Hussain, Vinod P. Shah, Carey B. Bottom, Ewart T. Cole, Larry L. Lesko, Henry Mallinowski, and Roger L. Williams. *Pharm. Res.* **17**(8): 962–966 (2000).

Footnote *b* for Table I should read: ^{b} P/P = ≥75% in water; F/P = ≤75% in water, but ≥75% in SFG with pepsin; and F/F = ≤75% in both water and SGF with pepsin.

On the Heterogeneity of Drug Dissolution and Release. By Panos Macheras and Aristides Dokoumetzidis. *Pharm. Res.* **17**(2): 108–112 (2000).

The Eqs. (2), (3), and (4) should be written as follows:

$$\frac{dm}{dt} = \frac{A \cdot D}{\delta}\left(C_s - \frac{m}{V}\right) \tag{2}$$

$$m = C_s V(1 - \exp(-Kt)) \tag{3}$$

$$K = \frac{A}{\delta} \cdot \frac{D}{V} \tag{4}$$

Also, the fraction C_s/V (page 108, right column, line 9) should be written as $C_s V$.

Differences in the Intracellular Distribution of Acid-Sensitive Doxorubicin-Protein Conjugates in Comparison to Free and Liposomal Formulated Doxorubicin as Shown by Confocal Microscopy. By Ulrich Beyer, Barbara Rothen-Rutishauser, Clemens Unger, Heidi Wunderli-Allenspach, and Felix Kratz. *Pharm. Res.* **18**(1):29–38 (2001).

On page 29 the affiliations should have appeared as:

Ulrich Beyer,[1] Barbara Rothen-Rutishauser,[2] Clemens Unger,[3] Heidi Wunderli-Allenspach,[2] and Felix Kratz[3,4]

[1]Present address: medac GmbH, Theaterstrasse 6, 22880 Wedel, Germany.
[2]Biopharmacy, Department of Applied BioSciences, Winterthurerstrasse 190, CH-8057 Zuerich, Switzerland.
[3]Tumor Biology Center, Department of Medical Oncology, Clinical Research, Breisacher Straße 117, D-79106 Freiburg, Germany.
[4]To whom correspondence should be addressed. (e-mail: felix@tumorbio.uni-freiburg.de)